30 C
Kolkata
Saturday, June 12, 2021

Biogen stock heads for biggest weekly rally in more than 2 decades, UBS analyst targets more gains

Facebook
Twitter
Pinterest
WhatsApp


Shares of Biogen Inc.
BIIB,
-4.36%
dropped 4.1% in afternoon trading Friday, to pull back from a six-year high, but UBS analyst Colin Bristow seems room for further gains to a record close. Even with the pullback, the stock has rocketed 39.0% this week, which would be the biggest weekly gain since it ran up 56.3% during the week ending Dec. 23, 1999, after the Food and Drug Administration approved the biotechnology company’s Alzheimer’s drug, Aduhelm. Bristow upgraded Biogen to buy from neutral, saying “like it or not, Aduhelm is going to get used.” He raised his stock price target to $463, which is 5.6% above the March 20, 2015 record close of $438.43, from $311. “We acknowledge there has and will continue to be physician/payor pushback but our doc checks indicate patient-led demand is already extremely high, with even bearish clinicians acknowledging there will be significant use (even if not under their own care),” Bristow wrote in a note to clients. The stock has run up 62.4% year to date, while the S&P 500
SPX,
+0.19%
has gained 12.9%.



Source link

Facebook
Twitter
Pinterest
WhatsApp
NEWS EDITOR
Breaking News Exchange is mainly to inform the public about events that are around them and may affect them. Often news is for entertainment purposes too; to provide a distraction of information about other places people are unable to get to or have little influence over. News can make people feel connected too.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

568FansLike
609FollowersFollow
142SubscribersSubscribe
- Advertisement -

Latest Articles